Nordic Nanovector: Safety Review Committee Approves Advancing to Final Dosing Regimen in Phase 1 Trial of Betalutin® in DLBCL |
| April 10, 2019 | April 2019 Bond Updates |
|
OSLO, Norway, April 10, 2019 /PRNewswire/ -- Nordic Nanovector ASA (OSE: NANO) announces that the Safety Review Committee (SRC) for the ongoing LYMRIT 37-05 clinical trial of single-administration Betalutin® (177Lu-satetraxetan-lilotomab) in patients with relapsed/refractory diffuse large ... |
| View more at: https://www.prnewswire.com:443/news-releases/nordic-nanovector-safety-review-committee-approves-advancing-to-final-dosing-regimen-in-phase-1-trial-of-betalutin-in-dlbcl-300829652.html |
| Related News |